Stand-by emergency treatment (SBET) of malaria in Spanish travellers: a cohort study by Ferrara, Pietro et al.
Ferrara et al. Malar J  (2018) 17:134  
https://doi.org/10.1186/s12936-018-2304-7
RESEARCH
Stand-by emergency treatment (SBET) 
of malaria in Spanish travellers: a cohort study
Pietro Ferrara1, Cristina Masuet‑Aumatell2,3, Fernando Agüero2,3 and Josep Maria Ramon‑Torrell2,3*
Abstract 
Background: Among strategies for malaria prevention, stand‑by emergency treatment (SBET) is a possible approach, 
but scarce evidences exists investigating travellers’ adherence and behaviours toward its use; therefore, the presented 
study aimed to determine travellers’ compliance toward the SBET when prescribed in travel clinics.
Methods: A prospective cohort study was performed at the Travel Health Clinic of the Hospital Universitari de 
Bellvitge, Barcelona, Spain, during 2017. The research was planned on survey‑based design, using pre‑ and post‑travel 
questionnaires.
Results: In the study period, of 5436 subjects who attended the HUB Travel Medicine Clinic, 145 travellers to malaria‑
endemic areas were prescribed SBET, and all patients agreed to participate in the study by completing the pre‑travel 
questionnaire. Approximately half the participants were women (n = 75, 51.7%), and the median age of all travellers 
was 29 years (range 13–57), mainly travelling to South‑East Asia (n = 69, 47.6%), with Indonesia and the Philippines 
as the most popular destinations. The length of travels had a median duration of 29 days (range 10–213). Of the 
recruited participants, 98 replied to the online post‑travel survey, reaching a response rate of 67.6%. A total of 62.2% of 
travellers to which SBET was prescribed did not buy and carry drugs while travelling abroad. No participants’ baseline 
or travel characteristic was shown to be significantly associated (p > 0.05) with this behaviour. Four women (4.1%) 
experienced fever and self‑administered SBET, without seeking medical attention. No malaria cases were observed.
Conclusions: This cohort study addressed travellers’ adherence and behaviour toward SBET, highlighting an incorrect 
use of the emergency treatment in case of presumptive malaria symptoms. This should be taken into account during 
pre‑travel consultation, since the success of this strategy for malaria prevention depends on travellers’ strong adher‑
ence to it.
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Background
Malaria prophylaxis differs substantially from traveller 
to traveller and from region to region, even within a sin-
gle country. This variability is a function of national rec-
ommendations, intensity of transmission, predominance 
of Plasmodium species and characteristics of the travel, 
such as destination, itinerary, duration, season and type 
of travel [1, 2]. Stand-by emergency treatment (SBET) is 
an approach based on traveller self-treatment to be used 
when a possible malarial infection could occur while 
overseas and a prompt medical evaluation is not possible 
because the traveller is staying in a remote area [3]. SBET 
should be presumptively self-administered when access to 
medical care is not available in less than 24 h and the trav-
eller develops a febrile illness consistent with malaria. The 
traveller should be advised that SBET is a temporary meas-
ure for suspected malaria. It is not counterfeit, and it will 
not interact adversely with the traveller’s other medicines, 
but a prompt medical evaluation remains imperative [3, 4].
The SBET prescription associated with mosquito avoid-
ance measures is due to a risk-benefits analysis, since the 
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incidence of adverse effects of chemoprophylaxis could 
outweigh the attack rate of malaria in areas at low risk of 
transmission [5, 6]. Moreover, the development of further 
anti-malarial drug resistances, associated with medica-
tion intake, and the presence of counterfeit medication in 
remote areas also foster SBET use [7].
The World Health Organization (WHO) provides 
general guidelines that travellers carrying SBET should 
observe, such as to consult a physician immediately if 
fever occurs 1  week or more after entering an endemic 
area, to start the SBET when medical care is not available 
within 24 h of the onset of fever and then to seek medi-
cal care as soon as possible for a complete evaluation and 
to exclude other illnesses and to use antipyretics to lower 
fever and reduce vomiting due to anti-malarial drugs [5].
Despite these guidelines, the medical community is 
currently debating the concept of SBET [8–10], and the 
available literature is partial insufficient to draw firm 
conclusions. Moreover, regarding the topic of travellers’ 
adherence to SBET, very little has been published [11–
14]; hence, the aim of this study was to determine travel-
lers’ compliance with prescribed SBET.
Methods
Study design
A prospective cohort study was performed in a travel 
clinic among travellers to areas at low risk for malaria 
who consecutively presented to the clinic in 2017 and 
agreed to be questioned about treatment use. Travellers 
who had completed their journey after December 31, 
2017 were excluded from the study. The information was 
gathered through two questionnaires: one that was com-
pleted face-to-face prior to the trip and during the medi-
cal visit (pre-travel questionnaire) and another that was 
completed by email from 2 to 3 weeks after the expected 
return date (post-travel questionnaire).
Setting
The study was conducted at the Travel Health Clinic 
at the Hospital Universitari de Bellvitge, in Barcelona, 
Spain.
Participants
Adults seeking medical advice at the travel clinic, 
between January 2017 and December 2017, before trav-
elling to areas where SBET could be prescribed, who 
agreed to participate in the study and to be contacted 
after the travel were included. SBET was prescribed 
to travellers who fulfilled the following indications: 
accepted SBET prescription and travelled to areas at 
low risk for malaria transmission, regardless of purpose 
of travel and duration; long-term travellers expected to 
be scarcely compliant to chemoprophylaxis; travellers 
without a definite route (such as backpackers). SBET 
was also proposed to travellers who refused chemopro-
phylaxis. Individuals who met the following criteria were 
excluded: people with severe renal impairment (creati-
nine clearance < 30  mL/min), pregnant women, women 
breastfeeding infants weighing < 5 kg, those not willing to 
participate or those who refused SBET prescription.
E-mail addresses were registered to contact the indi-
viduals and conduct the follow-up.
The participation was voluntary, participants were not 
offered any financial incentive and they were informed 
about their right to withdraw at any time without pen-
alty. The institutional ethical review board (University 
Hospital of Bellvitge) approved the study protocol and 
informed consent. All participants provided written 
informed consent. Confidentiality was maintained by 
omitting any personal identifying information from data 
collection.
Research instruments and outcomes measures
Participants were provided with information about 
malaria and its prevention measures, and instructed 
regarding SBET use. A pack of 12 tablets containing 
atovaquone 250  mg and proguanil 100  mg was pre-
scribed to each of them. Implementation of other effec-
tive interventions to avoid mosquito bites, such as 
frequent repellent use, appropriate clothing, insecticide 
residual spraying or sleeping under a bed net was also 
recommended.
For this survey-based prospective cohort study, two 
structured administered questionnaires were designed, as 
pre- and post-travel interviews. Both questionnaires were 
initially tested in a convenience sample of travellers to 
evaluate the design, clarity and comprehensibility of the 
items. To estimate the consistency of the responses, some 
probe questions were used. Based on respondents’ feed-
back, the initial version was amended, and some minor 
rewording of the questions was incorporated to simplify 
and improve the final version for clarity.
The questionnaires were administered by a trained 
medical doctor face-to-face and by e-mail 2–3  weeks 
after expected date of return by the same trained medi-
cal doctor. Additionally, checks of the Electronic Medical 
Records HC3 System [15] were performed to investigate 
travel-related health problems in the study population, as 
well as visits to GPs or emergency departments.
The pre-travel questionnaire assessed travellers’ socio-
demographic characteristics, collected as follows: age, 
gender, self-reported medical history (comorbidities, cur-
rent pharmacological treatments) and information about 
travel, such as country, itinerary, duration and purpose. 
Previous use of anti-malarial drugs and if they had ever 
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experienced any secondary adverse effects (AE) were also 
investigated.
Participants were also asked for their e-mail address 
to be contacted for completion of the post-travel ques-
tionnaire, which was delivered to all of them via profes-
sional online survey software  (Google® Forms) between 
2 and 3 weeks after their returns. All travellers received 
an email inviting them to complete the survey, acces-
sible via an embedded URL link. Non-respondents 
received a reminder 2  weeks later. A clear preliminary 
statement provided information to the cohort about the 
study and instructions and allowed participants to con-
firm their own informed consent to participate in the 
survey. The second research instrument, designed for 
capturing information about participants’ behaviours 
toward SBET use, comprised a question to investigate 
whether travellers carried anti-malarial medication dur-
ing travel abroad. When participants answered “Yes”, they 
were invited to provide information about the potential 
self-administration of the prescribed prophylaxis, the 
felt symptoms (fever, headache, chills, etc.), how long 
they self-administered drugs, any experienced AEs, and 
how fast they searched for medical assistance, if it was 
available.
Data analysis
Continuous variables were expressed as median and 
range; categorical variables were described as number 
and percentage. Due to their non-normal distribution 
(Kolmogorov–Smirnov test p value < 0.05), a Mann–
Whitney U test was used to assess differences between 
medians, and Chi square (χ2) or Fisher’s exact tests 
were used when needed to assess differences between 
categorical variables. All statistical tests were two-tailed, 
and a p value ≤ 0.05 was considered statistically signifi-
cant. Data were analysed using SPSS statistical software 
v. 21.0 (IBM SPSS Statistics for Windows, Armonk, NY, 
USA).
Results
From January to December 2017, 5436 travellers pre-
sented to the HUB Travel Medicine Clinic, and 1025 
intended to travel to malaria-endemic areas, being pre-
scribed SBET in 14.1% of cases (n = 145) as a reliable 
malaria self-treatment when the traveller planned to stay 
in remote areas with low risk for disease transmission. All 
of them agreed to participate in the study by completing 
the pre-travel questionnaire. A flow-chart of participants 
can be seen in Fig. 1.
The main characteristics of the study population and 
travel are listed in Table  1. Approximately half the par-
ticipants were women (n = 75, 51.7%), with a median age 
of 29 years (range 13–57), without previous use of anti-
malarial drugs (n = 129, 89.0%) travelling to Southeast 
Asia (n = 69, 47.6%), with Indonesia and the Philippines 
as the most popular destinations. Also, 10 subjects (6.9%) 
travelling to Africa were prescribed SBET, despite gen-
eral recommendations indicating chemoprophylaxis for 
Sub-Saharan regions. Of this sub-group, 8 had planned 
to travel to Ethiopia (n = 5) and South Africa (n = 3) and 
were prescribed with SBET because of the long length of 
stay or of the absence of a clear itinerary with an unpre-
dictable malaria risk, while the other 2 travellers (going 
to Ethiopia and Cameroon) refused traditional chemo-
prophylaxis. The median duration of travel was 29  days 
(range 10–213). No statistically significant differences (p 
Fig. 1 Flow chart of number of participants in the study
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value > 0.05) were observed above baseline characteristics 
between patients who answered the post-travel question-
naire and the missing ones.
Among travellers who had used atovaquone/proguanil 
as anti-malarial chemo-prophylaxis (n = 16) in previous 
travels, 12.5% of them (n = 2) were women of 50  years 
old (yo) and 26 yo who reported experiencing nausea and 
vomiting as AEs.
Of the recruited participants, 98 also completed the 
online survey for a total response rate of 67.6%; of those, 
only 37 (37.8%) actually carried anti-malarial drugs while 
travelling abroad, while 61 travellers to which SBET was 
prescribed did not buy the drugs before travelling. No 
participants’ baseline or travel characteristic was shown 
as significantly associated (p value > 0.05) with this 
behaviour.
The analysis of the post-travel questionnaires showed 
that 94 subjects (95.9%) did not declare fever or other 
health problems during or after the travel. Three women 
(4.1%) experienced fever only, and a fourth complained 
of fever and diarrhoea: all of them declared SBET 
self-administration more than 7  days after entering the 
endemic area; the 4 users did not seek medical care nor 
quicken their travel (Table  2). Furthermore, 2 of them 
reported implementing SBET during 3  days; one also 
declared general malaise and nausea after atovaquone/
proguanil consumption.
The consultation of regional Electronic Medical 
Records HC3 System [15] of all participants confirmed 
no malaria cases, nor other travel-related health prob-
lems in the rest of the study population. No visits to gen-
eral practitioners (GPs) or emergency departments were 
observed in the study and follow-up periods.
Discussion
This cohort study offers a first insight into travellers’ use 
of the SBET in Spain.
Because of travel characteristics, foremost the median 
length of stay of 29 days, staying in remote areas with low 
intensity of malaria transmission and a scarce number 
of imported cases from these areas, the study group was 
selected as a candidate of SBET strategy instead of anti-
malarial chemoprophylaxis.
The most noticeable data yielded through the online 
post-travel survey is about the consistent number of trav-
ellers who did not even carry atovaquone/proguanil while 
travelling abroad, with two-thirds of them (62.2%) not 
following medical prescriptions. This behaviour may be 
explained by the idea that going to areas with low risk for 
malaria infection falsely reassures travellers [16], leading 
them to believe it is unnecessary to buy drugs themselves. 
In this behavioural domain, there were no differences 
associated with travellers’ demographic profiles or travel 
characteristics, presenting it as a widespread perception 
[11]. This aspect represents an unpredictable widespread 
behaviour among travellers that should be taken into 
account during pre-travel medical care. These findings 
foster the idea that more studies are needed to investigate 
this domain, as well as the implementation of instructive 
Table 1 Characteristics of study population (n =145)
a Variables summarized by median and range
Gender
 Male 70 (48.3%)
 Female 75 (51.7%)
Age (in years)a 29 (13–57)
Area of destinations
 Africa 10 (6.9%)
 India and Nepal 17 (11.7%)
 Southeast Asia 69 (47.6%)
 Central America 19 (13.1%)
 South America 30 (20.7%)
Duration of travel (in days)a 29 (10–213)
Previous use of anti‑malarial drugs (atovaquone/progua‑
nil)
16 (11.0%)
 AE 2 (12.5%)
Table 2 Description of SBET users (n =4)
SBET Stand-by emergency treatment
* Missing information













1 22/F Thailand, Laos, and 
Vietnam
50 Fever 3 General malaise, 
nausea
No
2 27/F Indonesia 45 Fever 3 None No
3 28/F India 48 Fever and diarrhoea * None No
4 34/F Ethiopia 9 Fever * * No
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programmes designed to improve the level of compliance 
to SBET recommendations among travellers.
While it is well known that a large number of people 
travel without a pre-travel medical consultation [17, 18], 
a major interest of such a cohort is the relevant num-
ber of travellers that still travel without any protection 
against malaria, although they attended a specific travel 
clinic where they were informed about risks and received 
a medical prescription of SBET that could be collected 
from a pharmacy for less than € 5.
The vast majority of the respondents (95.9%) declared 
that they did not experience any possible malarial 
symptoms during travel. Only 4 responders took drugs 
because of the onset of fever without other symptoms 
for 3 women, and of fever and diarrhoea in a fourth user. 
Two SBET users also reported to have complied with the 
dosage of 4 tablets taken on a daily basis, during 3 days. 
Not all users sought medical attention nor interrupted 
their travel. None of these was confirmed as a malaria 
case from the consultation of regional medical records 
during the follow-up period.
Even if only represented by 4 travellers, the por-
tion of SBET users (4.1%) in this study is in concord-
ance with results reported by other published studies 
[11–14]. However, a general scarce level in the applica-
tion of medical advice was shown in this cohort, since 
these interviewees detailed an incorrect administration 
of the SBET regimen. This highlights two relevant issues, 
regarding the information provided to travellers during 
pre-travel care, as well as the risk of exposure to drug AEs 
due to their erroneous use. The use of a strong dose of 
atovaquone/proguanil in a short period of time increases 
the likelihood of AEs and toxicity, to which travellers 
might be needlessly exposed, such as the 22-yo user that 
also reported general malaise and nausea as atovaquone/
proguanil AEs. Also alarming is travellers’ perception of 
the emergency treatment as an alternative for medical 
care, although guidelines strongly recommend immedi-
ate medical consulting.
Prescription of this prevention strategy is currently 
increasing, with a natural change from chemoprophy-
laxis to SBET [19], due to travellers’ preferences for SBET 
itself more than traditional prophylaxis [20]. Indeed, 
several arguments support the concept of SBET in those 
areas with a low risk transmission: (1) the use of SBET, 
instead of chemoprophylaxis, reduces the likelihood of 
the development of AEs of the medication; (2) the devel-
oping of drug resistances and the presence of counterfeit 
anti-malarial drugs in these areas also lead healthcare 
professionals to indicate emergency treatment; (3) some 
travellers’ characteristics represent situations in which 
this option can be considered, such as travellers without a 
definite itinerary, short-stay travellers (such as those who 
travel for professional purposes) and those who move to 
remote areas or areas devoid of medical facilities.
While the smooth utility of SBET is ensured if instruc-
tions for use are followed, as this research showed, SBET 
is not a reliable choice for most travellers due to misuse.
Due to this lack of strong scientific evidence regarding 
the effectiveness of prophylaxis regimens other than tra-
ditional chemoprophylaxis, the current UK guidelines for 
malaria prevention in travellers place emphasis only on 
the implementation of interventions to avoid exposure, 
such as precautions against mosquito bites (frequent 
repellent use, appropriate clothing, insecticide residual 
spraying, sleeping under a bed net) or seeking medical 
advice as soon as symptoms develop, without the use of a 
specific anti-malarial [21].
The main limitations of the study are as follows. First, 
the number of travellers who visited the clinic to whom 
SBET was prescribed was limited as a real-world study; 
for this reason, and due to the likely multi-factoral 
nature, it was not possible to assess the barriers to their 
mis-implementation of pre-travel recommendations. 
Second, there is potential bias due to the use of a tracea-
ble and not anonymous online survey, where respondents 
could be influenced by researchers’ expectations or hide 
the actual incorrect behaviours. Consultation of regional 
medical records likely softened this limitation, even 
though participants may not have sought medical care 
for minor health problems, leading to underestimation of 
the actual incidence of travel-related health problems.
Despite these limitations, since the participants in this 
study represented the standard travel population, it is 
possible to state that the selected cohort is representa-
tive of the target population. Moreover, the enrolment of 
a consecutive cohort reduces problems of selection and 
participant bias.
Conclusions
In conclusion, the findings addressed travellers’ adher-
ence and behaviours toward SBET, expressing an 
incorrect use of the emergency treatment in cases of pre-
sumptive malaria symptoms. Substantial concerns about 
SBET itself as well as on the need to design and imple-
ment proven prevention measures for malaria arise from 
this information, and they should be taken into account 
during pre-travel consultation, since the success of this 
strategy for malaria prevention depends on travellers’ 
strong adherence to it.
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